article thumbnail

Cell culture Q&A: Solving biomanufacturing challenges with Recombinant Insulin supplementation

Pharmaceutical Technology

It is no exaggeration to say that the world changed in the early 80s when insulin was expressed synthetically in microorganisms for the first time. This breakthrough led to a recombinant (biosynthetic) and thereby safer therapy for diabetes than the animal-sourced insulin which had been used since 1922.

Insulin 130
article thumbnail

Diabetes researchers discover the potential of CIDEC protein to mitigate obesity-related cardiometabolic disease

Medical Xpress

A team of researchers from Ohio University's Heritage College of Osteopathic Medicine has recently discovered a novel role of human-CIDEC gene in improving metabolic dysfunction and cardiovascular health.

Protein 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Breast cancer drug repurposed for congenital hyperinsulinism

Drug Discovery World

In a world first, Sidra Medicine, a member of Qatar Foundation, has pioneered a new treatment protocol for a young infant with congenital hyperinsulinism. The findings were published in the New England Journal of Medicine. The medication regulates cell growth, proliferation and development and insulin signalling.

Drugs 52
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

The next wave of medicine is well on course to be cell and gene-based. In September 2021, GlobalData figures revealed there to be 1,320 industry-sponsored regenerative medicine and advanced therapy trials ongoing worldwide. Meanwhile, the pharma industry is undergoing somewhat of a transformation itself.

Drugs 295
article thumbnail

Velocity Investigators Active at the American Diabetes Association (ADA) 83rd Scientific Sessions

Velocity Clinical Research

The prolific researchers also had findings simultaneously published in the New England Journal of Medicine and The Lancet. Dr. Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In Trial results were presented at the ADA sessions and published in NEJM.

Insulin 52
article thumbnail

New Approaches and Evolutions to Reshape the Diabetes Management and Care

Delveinsight

In Type 2 diabetes, the body cells become resistant to insulin. The pancreas produces insulin that helps glucose get into cells to be used for energy. Due to Type 2 diabetes, either the body doesn’t make enough insulin or it doesn’t use insulin properly as a result the blood glucose or blood sugar gets too high.

Insulin 94
article thumbnail

Biologic Therapeutics Development, Part 1: Definition and Distinct Characteristics

Camargo

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Recombinant therapeutic proteins. Fusion proteins. Gene and cellular therapies. Growth factors. Interferons.